With potential launches nearing, Zai taps investors for $200M

Eight months after raising $150 million in a follow-on, Zai has returned to the well to raise $200 million in an upsized offering as it prepares for a pair of potential launches in mainland China. The new money roughly doubles the company's cash reserves.

By year end, Zai Lab Ltd. (NASDAQ:ZLAB) hopes to begin marketing PARP inhibitor Zejula niraparib in China as maintenance therapy for ovarian cancer following response to chemotherapy. Zai already markets Zejula in Hong Kong; its partner, the Tesaro unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), markets it in the West...